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Asthma is a heterogeneous disease comprising of multiple phenotypes and affects
patients from childhood up to old age. In this review, we summarize the current
knowledge on the similarities and differences in asthma across different age-groups, with
emphasis on the perspective from primary care. Despite the similar disease presentation,
phenotyping studies showed that there are differences in the distribution of phenotypes
of asthma presenting in childhood compared to that in adulthood. Whereas, asthma
with early age of onset tends to be of the atopic phenotype, the disease shifts toward
the non-atopic phenotypes at later ages. Studies within primary care patients aiming to
elucidate risk factors for future asthma exacerbation have shown pediatric and elderly
patients to be at higher risk for future asthma attacks compared to other adult patients.
Regardless, both pediatric and adult studies demonstrated previous asthma episodes
and severity, along with high blood eosinophil to predict subsequent asthma attacks.
Differences in childhood and adult asthma are not limited to the underlying phenotypes
but also extends to the challenges in the diagnosis, treatment, and management of the
disease. Diagnosis of asthma is complicated by age-specific differential diagnoses such
as infectious wheezing and nasal obstruction in children, and aging-related problems
such as heart disease and obesity in the elderly. There are also age-related issues leading
to decreased disease control such as non-adherence, tobacco use, difficulty in using
inhalers and corticosteroid-related side effects which hinder asthma control at different
patient age-groups. Several clinical guidelines are available to guide the diagnosis
and drug prescription of asthma in pediatric patients. However, there are conflicting
recommendations for the diagnostic tools and treatment for pediatric patients, posing
additional challenges for primary care physicians in working with multiple guidelines.
While tools such as spirometry and peak flow variability are often available in primary care,
their usage in preschool patients is not consistently recommended. FeNO measurement
may be a valuable non-invasive tool which can be adopted by primary physicians to
assist asthma diagnosis in preschool-age patients.
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INTRODUCTION
The term “asthma” encompasses1 heterogeneous phenotypes of
conditions sharing similar symptoms yet different underlying
causes and prognosis (1, 2). Depending on the age of
presentation, symptoms of asthma may represent different
phenotypes of the disease, each with its own challenges in the
diagnosis, management, and treatment. A better understanding
of the different subsets of asthma is hoped to assist us to better
diagnose, manage, and treat this disorder.
Primary care represents the frontline of patient management
and not all patients with asthma require referral to secondary care
(3). Thus, this article aims to describe the age-related phenotypes
of asthma and the challenges presented by asthma across different
age groups, with emphasis on insight from primary care.
ASTHMA ACROSS AGES
Phenotypes of Asthma
The traditional method of asthma phenotyping involves
grouping of asthma by characteristics such as the age of onset,
trigger, atopic status, and presence of biomarkers, in a so-called
“biased” approach to phenotyping (4–6). It is well-known that
early-onset asthma represents a distinct phenotype compared
to adult-onset asthma. Adult-onset asthma may also be further
divided into long-standing asthma, asthma which remitted at
childhood and subsequently relapsed, and new onset adult
asthma (7).
Cluster analysis presents an unbiased statistical approach to
phenotype asthma by grouping them into clusters withmaximum
similar characteristics within clusters and minimum similarity
between clusters (Table 1). Haldar et al. conducted a cluster
analysis from both patents with milder asthma presenting in
primary care, as well as patients with refractory asthma diagnosed
in secondary care (2). The study identified 3 and 4 separate
clusters of asthma from the respective populations, 2 of which
were identified from both populations. Two clusters denoted with
early onset were both accompanied with positive atopic status,
one of which had minimal signs of eosinophilic inflammation.
Clusters of late-onset asthma include a cluster of obesity-
related non-eosinophilic asthma predominant in females and
a male-predominated cluster predominantly marked by active
eosinophilic inflammation but fewer symptoms. Both late-onset
clusters also consisted of lower proportion of patients with
positive atopic status compared to the early onset clusters.
A cluster analysis which combined severe asthma and non-
severe asthma patients recruited into the Severe Asthma Research
Program (SARP) identified 5 clusters of asthma (8). Similar to
the characteristics of the clusters identified by Haldar et al.,
clusters associated with early age of onset were also associated
with higher atopic status while those with later-onset were
less atopic. Another cluster analysis study was conducted on
children (6–11 years) and adolescent to adult patients (>11 years)
with severe or difficult-to-treat asthma from the TENOR (The
Epidemiology and Natural History of Asthma: Outcomes and
Treatment Regimens) study (9). Five clusters were identified
within both age-groups differentiated by demographics, a topic
status, tobacco exposure (in children), and aspirin sensitivity (in
adolescent to adults). Interestingly, in contrast to adolescent and
adult patients, none of the five children clusters had significantly
different asthma outcomes (within the next 12 months) among
each other, though this is likely due to the population of the study
being limited to severe asthma patients.
Results from both classic “biased” phenotyping studies and
cluster analysis studies thus confirmed that early onset asthma
is more likely to be atopic in nature, while adult-onset asthma
tends to have non-atopic causes, primarily obesity. Figure 1
illustrates a simple representation of this relationship between
the atopic status of asthma and age as previously reviewed by
Wenzel et al. (6).
Current asthma guidelines state that more research on the
value of asthma phenotyping to guide treatment is required
(10, 11).
Severe Asthma Across the Age
An estimated 5–10% of asthma patients suffer from a severe
form of asthma (12). Despite the rarity, severe asthma poses high
healthcare resource burden (13). The GINA (Global INitiatives
for Asthma) guideline defined severe asthma as asthma which
requires high dose ICS (inhaled corticosteroid)/LABA to
prevent it from being uncontrolled or asthma which remains
uncontrolled despite this treatment (10). Regardless, there is
currently no universally accepted definition for severe asthma,
preventing accurate estimation of its global prevalence, which is
further contributed by the absence of a global registry for this
subset of asthma until the recent creation of the International
Severe Asthma Registry (14).
A recent review by Guilbert et al. highlighted the differences
between adult and pediatric severe asthma (15). Compared to
the adult counterpart, severe asthma in children had a more
rapidly changing phenotype. They were also characterized with
higher exhaled nitric oxide, IgE, and eosinophil levels. Despite
the differences in pediatric and adult severe asthma, the current
treatment guidelines for pediatric severe asthma is currently
based on extrapolation from adult studies (15). Thus, there is a
need for better guidelines on severe childhood asthma.
RISK PREDICTION OF ASTHMA
Asthma exacerbation is a major cause of quality of life disruption
and healthcare resource consumption. Thus, a part of asthma
management includes managing the risk for future asthma
exacerbations/attacks on top of maintaining symptom control
(10, 16). The GINA provides a guideline for assessment of asthma
exacerbations in primary care setting (10). The guideline suggests
documentation of symptom histories such as the onset, severity,
potential risk factors, and current therapy, along with physical
examination and objective measurements such as pulse oximetry
and peak expiratory flow measurement (for patients> 5 year).
Numerous studies have been conducted to investigate
potential risk factors for future asthma exacerbations (Table 2).
Observational studies using primary care data have identified
factors such as previous asthma attacks and medication usage in
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TABLE 1 | Clusters of asthma phenotypes.
Population analyzed Additional patient details Clusters Identified
Haldar et al. (2)
1. Primary care (n = 184) Age range: 18–65 years 1. Early-onset atopic (n = 61)
2. Obese, non-eosinophilic (n = 27)
3. Benign (n = 96)
2. Secondary care (n = 187) Age range: not specified 1. Early-onset atopic (n = 74)
2. Obese, non-eosinophilic (n = 23)
3. Early symptom predominant (n = 22)
4. Inflammation predominant (n = 68)
Moore et al. SARP study, 2010 (8)
12–80 years old (n = 726), 304 fulfilled
criteria for severe asthma
Primary/secondary: not specified 1. Early-onset atopic, normal lung function and low healthcare
utilization (n = 110)
2. Early-onset atopic, higher medication requirement (n = 321)
3. Late-onset, less-atopic, obesity-related, lower lung function, and
more daily symptoms and healthcare utilization (n = 59)
4. More severe, long-standing, early-onset, atopic, reversible lung
obstruction, high ICS usage (n = 120)
5. More severe, long-standing, late-onset, less-atopic, less-reversible
lung obstruction, high ICS usage (n = 116)
Schatz et al. TENOR study, 2014
(9)
6–11 years old (n = 518) Patients recruited from “managed
care organizations, community
physicians or group practices, and
academic centers”
1. White race with no tobacco exposure (n = 115)
2. Female cluster (n = 81)
3. Non-atopic (n = 162)
4. Passive smoke exposed (n = 87)
5. Non-white race (n = 73)
≥12 years old (n = 3,612) 1. White female adult onset, low IgE (n = 1262)
2. High atopic cluster (n = 659)
3. Male cluster (n = 664)
4. Non-white cluster (n = 596)
5. Non-white race (n = 431)
ICS, Inhaled corticosteroid.
and biomarkers such as blood eosinophil to predict exacerbations
in subsequent years (17, 18).
Knowledge of the risk factors for asthma attacks in children
is scarce, and even less is known in preschool asthma, where
exacerbation may have viral triggers (19). Swern et al. conducted
a post-hoc analysis of 2–5years old patients (n = 689) previously
enrolled in a randomized control trial (20) The trial included
patients with physician-diagnosed asthma defined as≥3 episodes
of asthma symptoms in the past year including but not limited to
cough, wheezing and shortness of breath. The study identified a
combination of daytime cough, daytime wheeze, and night-time
β2-agonist use to be predictive of exacerbation in the following
day. However, this study did not report risks for exacerbations
further than 3 days after the identification of risk factors.
A very recent study by Bloom et al. reported the exacerbation
risks on the general asthma population across different age-
groups including patients under 5 years old within the UK’s
national electronic healthcare records (3). Interestingly, patients
≥55 years and<5 years had the highest rate for exacerbations, in
comparison to adolescents (5–17 year) and adults (18–54 years).
Regardless of the age groups, higher asthma severity (as defined
by the BTS [British Thoracic Society] treatment steps) was a
significant predictor for annual exacerbation rate and time to
next exacerbation, especially within the<5 years group.
Results on older children and adolescents confirmed
the findings of the adult studies, i.e., recent asthma attacks
and blood/systemic eosinophilia were consistently reported
as predictors for future attacks (17, 18, 21–25). A recent
observational study combining data from 2 primary care
databases in the UK also reported recent asthma attacks,
previous consultation for lower respiratory infections,
blood eosinophils > 400/µL, and younger age to be
indicative of high-risk for future asthma exacerbation in
children 5–12 years of age (23). Another large observational
study using general practice data of Dutch children 5–
18 years old reported asthma exacerbations and asthma
treatment in the preceding year and younger age to be
risk factors for severe asthma exacerbations (24). While
blood eosinophil level of ≥300 cells/uL was not a risk factor,
children with heightened blood eosinophil had shorter time
till exacerbation.
Interestingly, in contrast to adult population studies where
older age was associated with increased risk (17, 18), studies
in children reported younger age to be associated with
higher risk for asthma attacks/exacerbations (23, 24). This
confirms the observation by Bloom et al that patients at
both ends of the age spectrum were at the highest risk for
exacerbations (Figure 2) (3).
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FIGURE 1 | Illustration of the relationship between asthma phenotypes and the age of onset. At younger age, asthma is predominated by the atopic phenotypes,
which are gradually phased out by non-atopic phenotypes such as obesity-related asthma at adulthood.
DIAGNOSTIC CHALLENGES ACROSS AGE
There is still a very clear lack of understanding of asthma in
children under 5 years, and diagnosis of asthma within the
preschool age is challenging due to the lack of proper guideline
and definition (26). In this age group, symptoms of wheezing and
cough are very common butmay be the result of acute respiratory
infections instead of asthma (Figure 3) (27, 28). The Tucson birth
cohort (USA) identified three distinct phenotypes of wheezing
in the first 6 years of life: transient early wheezing, late onset
wheezing and persistent wheezing (29, 30). The result from
subsequent follow-up reported that not all children who wheezed
developed asthma in later childhood, although children with
atopic wheezing were the most likely (30). Thus, differentiating
transient symptoms from symptoms of the more persistent
asthma poses a challenge in early age.
The GINA (10) and CTS (Canadian Thoracic Society)
(31) guidelines recommend consideration of symptomatology,
potential triggers and family history to assist in clinical decision
making for this age group of patients. The guidelines additionally
recommend observing for signs of airway obstruction and
reversibility with inhaled bronchodilators to assist in diagnosis.
Similarly, the Australian Asthma Handbook (32) and NICE
guideline (33) recommend treating preschool patients with
suspected asthma based on clinical observation and conduct
objective tests only after 5 years of age.
Objective tools recommended by the clinical guidelines to
diagnose asthma across different age groups are summarized
in Table 3. Lung function tests, primarily spirometry, are
recommended to confirm asthma diagnosis in school-aged
children and adults within primary care practice (10, 11, 16, 33–
35). However, in many countries, spirometry is not available to
primary care, and conducting lung function tests on patients
<5 years old is challenging due to their inability to produce
consistent lung function readings (Figure 3) (10, 26, 28, 36).
The BTS guideline thus does not recommend lung function
measurement to guide asthma management in this age group
(16). A joint statement by the American Thoracic Society (ATS)
and European Respiratory Society (ERS) suggested taking only
one satisfactory measurement, instead of the ideal of at least two
separate measurements to accommodate pediatric patients (36).
The GEMA emphasizes the need for nursing supervision and
suggested measurement of FEV0.5 instead of FEV1 in preschool
children 3 years and above (11).
FeNO (Fractional concentration of exhaled Nitric Oxide) is an
inflammatory biomarker whichmay indicate the presence of type
2 asthma (asthma characterized by Type-2 inflammation). The
NICE (National Institute for Health and Care Excellence) (33)
and GEMA (Spanish Guideline on the Management of Asthma)
(11) guideline recommends FeNO measurement for asthma
diagnosis. The GINA, on the other hand, do not recommend
the usage of FeNO to aid asthma diagnosis in adults, with
the argument that FeNO may be elevated in other respiratory
conditions, and is not elevated in other asthma phenotypes such
as neutrophilic asthma (10). However, the guideline recommends
FeNO measurement in preschool-age patients. In agreement
with this, a prospective study in a hospital setting reported
elevated FeNO level during preschool to be predictive of school-
age asthma (37). Additionally, a randomized control trial based
on 24 primary care centers and one hospital showed that high
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TABLE 2 | Risk prediction of future asthma exacerbations/hospitalization*.
References Population Age Definition of asthma Outcome Predictive factors
PEDIATRIC
Swern et al.
(20)
Patient from double-blinded
multicenter RCT
2–5
years
Physician-diagnosed asthma: At least
3 episodes of asthma symptoms
such as cough, wheeze, shortness
of breath
Asthma attacks • Daytime cough
• Daytime wheeze
• Night-time β2-agonist
Bloom et al.
(3)
Primary care <5 years
and 5–17
years
Patients with read codes for asthma Annual asthma
exacerbation rate and
time to first
exacerbation
• Higher asthma severity
Haselkorn
et al. (21)
Severe asthma children
recruited from “Managed
care organizations,
community physicians or
group practices, and
academic centers”
6–11
years
Diagnosed with severe asthma or
mild/moderate asthma considered to
be difficult-to-treat by site specialist.
Future severe
exacerbation
• Recent exacerbation
• Non-white race (vs. white)
• 3-4 allergic triggers
• Poor asthma control
Covar et al.
(22)
Patient from double-blinded
multicenter RCT
6–14
years
Mild-moderate persistent asthma:
Diary-reported symptoms or
β-agonist use (not including
pre-exercise), or mean morning and
evening peak flow < 80%.
Asthma exacerbation • Baseline exacerbation
Turner et al.
(19)
Primary care 5–12
years
Read Code for asthma diagnosis. Asthma attack in 1 year
follow-up
• Higher GINAmanagement step
• Consultation for LRTI
• Blood eosinophil >400/µL
• Baseline asthma attacks
• Younger age
• Lower peak expiratory flow
Engelkes
et al. (24)
Primary care 5–18
years
Algorithm-validated from list of
patients with ICD code and free-text
of asthma
Severe asthma
exacerbation
• Younger age
• Exacerbations in the previous
year
• Use of any asthma medication
Time until next
exacerbation
• Younger age
• Female gender
• Exacerbations in the previous
year
• Respiratory infection in the
previous year
• Asthma specialist visit in the
previous year
• ICS prescription
• Blood eosinophil >300/µL
• Comorbid eczema
ADULTS
Bloom et al.
(3)
Primary care 18–54
years
and ≥55
years
Patients with Read Codes for asthma Annual asthma
exacerbation rate and
time to first
exacerbation
• Higher asthma severity
Kerkof et al.
(25)
Primary care patients with
secondary care data linkage
≥5 years Active asthma defined as having
diagnostic Read Codes for asthma,
no code for resolved asthma, and at
least 2 prescriptions for asthma.
Asthma-related
hospital readmission 1
year after discharge
• Blood eosinophil count ≥0.35
× 109 cells/L
Blakey et al.
(17)
Primary care 12–80
years
Active asthma defined as having
diagnostic Read Codes for asthma,
no code for resolved asthma, and at
least 2 prescriptions for asthma.
Asthma exacerbations
in 2 years follow-up
period
• Baseline (1 year) asthma
exacerbations
• Older age, female gender,
current smoking, overweight
• Co-morbid rhinitis, eczema,
GERD, nasal polyps, or
anaphylaxis
• High blood eosinophil count
• Higher daily SABA dose
• NSAID, LTRA or LABA
prescriptions
(Continued)
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TABLE 2 | Continued
References Population Age Definition of asthma Outcome Predictive factors
• More acute OCS course
• More asthma-related hospitalization
• More primary care visits
• Lower PEF%
Price et al.
(18)
Primary care 12–80
years
Patients with recorded
physician-diagnosis for asthma and
no other chronic respiratory diseases.
≥2 severe asthma
exacerbations in 1 year
follow-up
• Older age, female gender,
current smoker, overweight,
• Blood eosinophil >400/µL
• Co-morbid anxiety, diabetes,
eczema, GERD, rhinitis
• NSAID prescriptions
• Higher asthma treatment step
(BTS-SIGN)
• General practice consultation
for LRTI
• Outpatient asthma attendance
• Having acute OCS courses
• >400 µg/day SABA dose
• >800 µg/day ICS dose
(FP equivalent)
*Studies which analyzed pediatric and adult patients as a single group are categorized as adult studies. BTS, British Thoracic Society; FP, Fluticasone propionate; GERD,
Gastroesophageal reflux disease; GINA, Global Initiatives for Asthma; ICS, Inhaled corticosteroid; LABA, long-acting β-agonists; LRTI, Lower respiratory tract infection; LTRA, Leukotriene
receptor antagonists; NSAID, Nonsteroidal anti-inflammatory drugs; OCS, oral corticosteroid; PEF, Peak expiratory flow; SABA, short-acting β-agonist; SIGN, Scottish Intercollegiate
Guidelines Network.
FIGURE 2 | Illustration of the risk factors for future asthma exacerbations.
FeNO level was associated with improved Asthma Control
Questionnaire 7 items (ACQ7) score following ICS treatment
(38). Therefore, FeNO measurement can be a non-invasive
measure conducted in primary care practices to assist asthma
diagnosis in preschool children and identifying patients whomay
benefit from ICS treatment.
Another available tool to assist primary care practitioners to
predict whether the presenting wheezing symptoms in preschool
children will develop into asthma by school age is the modified
version (mAPI) (39) of the Asthma Predictive Index (API)
created based on data from the Tucson cohort study (30, 40). The
mAPI has been previously shown in an asthma birth cohort study
to have high positive predictive capability for asthma at 6, 8, and
11 years based on mAPI score at the first 3 years of life (41).
Older age presents another diagnostic challenge distinct from
that in younger patients (Figure 3). Symptoms of asthma in old
age may be masked by aging-associated changes in pulmonary
and other physiological functions (10, 42) and the presence
of multiple co-morbid conditions (43). These factors lead to
underdiagnosis of asthma within the elderly. The decreased
respiratory capacity in the elderly may also make it difficult
to conduct lung spirometry, as such the National Institute
of Aging recommended alternative techniques which do not
require inspiratory efforts such as imaging and forced oscillation
(42) The GINA guideline recommends physical examination,
such as electrocardiogram and chest x-ray, to aid in the
diagnosis of elderly asthma in addition to the routine clinical
history taking (10).
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FIGURE 3 | Challenges related to asthma treatment across age. Adapted with permission from: Kaplan A, Covar R, Vanderwalker M. An update on treatment options
for children and adults with asthma. Manuscript in Preparation.
Diagnosis of asthma is further complicated by differential
diagnosis for symptoms whichmaymimic asthma. Asmentioned
above, wheezing and cough in children are likely to be infectious
in nature. Non-infectious, non-pulmonary related causes of
cough and wheeze, such as gastroesophageal reflux, airway
obstruction due to foreign bodies, and congenital heart disease,
should also be ruled out before the diagnosis of asthma in
children (10). In old age, age-related problems such as heart
disease and obesity are the major contributors to differential
diagnosis. Chronic obstructive pulmonary disorder (COPD)
is also a common cause of misdiagnosis in primary care
due to overlapping symptoms with asthma (44). In addition,
they may occur concurrently, in a term known as asthma-
COPD overlap (ACO). Careful symptom history taking and
post-bronchodilator spirometry to test for reversible airway
obstruction are recommended to differentiate asthma from
COPD and ACOS (10).
THERAPY ISSUES AT DIFFERENT AGES
Differences in Treatment Guidelines
The GINA guideline provides a step-wise management approach
for treatment andmanagement of asthma (10). The 2018 updated
guideline still recommends as-needed short-acting β-agonists
(SABA) for reliever treatment of asthma attacks and ICS as the
initial controller medication for asthma, with addition of long-
acting β-adrenoceptor agonists (LABA, as combination therapy
with ICS), leukotriene receptor antagonists (LTRA) or stepping
up of dosage as required for adolescent and adults patients above
the age of 12 (10). Recommendations from other guidelines
are similar (11, 16, 32–34): initial reliever with SABA, initial
preventer treatment of ICS, and when needed, adding LABA in
combination with ICS.
Initial treatment option for children 5–12 years follows
that of older patients. However, LABA as the initial add-
on is not recommended by the GINA (10) for this age
group, in contrast to the BTS (16) recommendation. The
CTS recommends LABA if stepping up ICS dosage fails
to achieve control (34). Alternatively, tiotropium, a long-
acting muscarinic antagonist (LAMA), administration by
mist inhaler can be prescribed as an add-on in children
≥12 years and adults. LAMA is however not indicated
for children <12 years by the GINA (10) and BTS (16)
guidelines, though it is indicated for children ≥6 years in the
US (45).
The GINA guideline dedicates a section outlining a step-
by-step treatment guideline for children 5 years and younger,
however, the current guideline is based on more limited evidence
(10). Similar to older patients, (SABA) should be given as initial
reliever upon presentation of wheezing. When necessary, i.e.,
symptoms suggestive of asthma or frequent wheezing episode, a
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TABLE 3 | Objective tests recommendation in each age-groups and availability in primary care.
Preschool (<5 years)* Children (5–12 years) Adolescent and adults (>12
years)
Availability in primary
care
Peak flow variability Not recommended by BTS Recommended by GINA, CTS, and
NICE; Not recommended by BTS
Recommended by GINA, BTS (in
adults), CTS, GEMA and NICE.
Available
Spirometry Not recommended by
GINA† and BTS
Recommended by GINA, BTS, CTS,
GEMA, AAH, and NICE
Recommended by GINA, BTS,
CTS, GEMA, AAH, and NICE
Available
FeNO Recommended by GINA,
GEMA, and BTS (for
3–4years)
Not recommended by GINA;
Recommended by NICE and BTS
(for eosinophilic asthma)
Not recommended by GINA;
Recommended by NICE, GEMA,
and BTS (for eosinophilic
asthma)
Not usually available
Bronchial provocation test Not recommended by GINA Recommended by GINA, BTS, AAH,
and CTS
Recommended by GINA, BTS,
CTS, AAH, and NICE (at >17
years)
Available in speciality
clinics also
Allergen sensitization Recommended by GINA
and GEMA but not
conclusive (doesn’t exclude
nonatopic asthma)
Recommended by GINA, GEMA,
and BTS but not conclusive; Not
considered essential by AAH.
Not recommended by NICE
Recommended by GINA, GEMA,
and BTS but not conclusive
Not recommended by NICE
Available through
speciality referral
Chest X-ray Recommended by GINA,
BTS, and CTS
Recommended by BTS Recommended by BTS, and by
GINA (in elderly).
Typically available
*NICE guideline does not recommend any objective tests to guide asthma diagnosis in children <5years
†
According to GINA, children 4–5 years may undergo spirometry with
guidance. GINA, Global Initiatives for Asthma; BTS, British Thoracic Society; AAH, Australian Asthma Handbook; NICE, National Institute for Health and Care Excellence; CTS, Canadian
Thoracic Society.
low dose of ICS is recommended as the initial controller therapy.
Similarly, GEMA (11) and Australian Asthma handbook (32)
recommended initial SABA preventer with addition of low dose
ICS when necessary. The BTS (16) guideline recommends SABA
for reliever therapy together with low-dose ICS as the preventer,
while the CTS guideline for preschool patients (31) recommends
daily low-dose ICS as first-line therapy or SABA if symptoms
were mild or infrequent. LTRA is recommended as an alternative
to ICS by the GINA (10), GEMA (11), Australian Asthma
Handbook (32), and BTS (16) but is not recommended for use by
the CTS (31). If symptoms remain inadequately controlled with
low-dose ICS, the GINA, GEMA and CTS guidelines recommend
stepping-up to medium dose ICS, but this is not recommended
by the BTS (16).
There is a lack of guideline on the treatment for asthma
in elderly patients. Treatment of asthma in the elderly faces
additional challenge due to poorer asthma control. However,
more studies are required to determine whether this is due to
decreased treatment response, difficulty with inhaler technique,
or poorer adherence (43).
Challenges in Control
Adherence to inhaled corticosteroid (ICS) treatment is a
key factor for reduction of exacerbation and achievement
of asthma control. Yet, non-adherence toward ICS is
constantly reported to be a very common occurrence,
as high as 80% among asthma patients (46, 47). Various
factors influencing adherence have been previously
described, including educational level and confidence in
the treatment (48).
One of the factors influencing adherence includes changes
in attitude across ages. Younger children depend on parental
intervention for medication, thus it is not surprising that
parental concerns on medication to be influential toward
adherence in pediatric asthma (49, 50). Improvement of
adherence in pediatric patients should focus on parents and
caregivers. Interestingly, pediatric asthma therapy adherence
has been reported to be inversely correlated with children’s
age despite the supposedly increased understanding of
their condition (50, 51). This could suggest the presence
of teenage-related intentional non-adherence, which may
be due to several factors such as teenage rebellion, or
embarrassment of using prescribed inhaler therapy due to
peer pressure (48).
In elderly patients, non-adherence may stem from the
patients’ struggle due to memory loss coupled with the
complexity of the treatment regimen (42). This issue is further
exacerbated by the multiple comorbidities in elderly asthma
patients which may lead to an increased number of medications,
also known as polypharmacy, which subsequently impacts
asthma control (52).
Another factor which may negatively impact treatment
success is improper inhalation technique, a problem repeatedly
reported to commonly occur regardless of the ICS device type
(53, 54). The extensive list of possible DPI and MDI device
errors and their association with poor asthma outcomes were
recently described in a study utilizing primary care records of
7 European countries and Australia (CRITIKAL study) (54).
Among the errors reported to be associated with exacerbation is
insufficient inspiratory effort for DPI device. This error is well-
established to be a major challenge in preschool children and
elderly patients (55). AnMDI device (28) or soft mist inhaler (56)
with properly designed valved holding chamber is more suitable
for preschool children.
Frontiers in Pediatrics | www.frontiersin.org 8 May 2019 | Volume 7 | Article 162
Kaplan et al. Asthma Across the Ages
Smoking has been consistently reported to hinder response
to ICS therapy (57, 58), and poor asthma control was associated
with smoking status based on an interview of over 10,000
primary care patients aged 12 years and older (59). The
BTS guideline recommends higher ICS dose in patients
who are current or ex-smokers (16). Smoking remains a
global health behavioral problem from teenage to adulthood,
with a median reported global prevalence of 10.7% (range
1.7–35.0%) between 2012 and 2015 (60). A recent study
on the impact of ICS adherence on asthma exacerbation
and control within primary care reported one-third of
their patients to be active smokers (47). Tobacco smoking
thus represents another “wrench in the gears” in achieving
asthma control.
Despite the recommendation for ICS, concerns remain
regarding the associated side-effects, which have in turn been
reported to negatively impact patient adherence toward ICS
treatment (61). ICS is known to be associated with various local
side effects such as oral thrush (candidiasis) and hoarseness
(62, 63). A previous study reported 63.3% of children under
6 years of age to be affected (64). In addition to local side
effects, ICS treatment may also result in growth retardation in
children (65). It is therefore recommended to use the lowest
ICS dosage for this age group and to monitor for reduced
growth velocity (10). The Canadian Society of Allergy and
Clinical Immunology (CSACI) also recommended monitoring
for adrenal suppression for children and adolescents receiving
high dose ICS (66). Another potential systemic side effects of ICS
include osteoporosis (which leads to bone fractures), cataracts
and diabetes, which pose additional concern on ICS use in older
patients (65). Patients administered high dose ICS over a long
period (more than 3 months) should thus be monitored for any
potential side effect (10, 16).
Issues in Therapy Response
In addition to the challenges in diagnosis, old age poses additional
challenges in the treatment of asthma due to decreased response
to bronchodilator therapy (3, 67, 68). Knowledge and guidelines
on elderly asthma are limited, and clinical trials tend to exclude
elderly patients due to the presence of co-morbidities (43).
Unlike in preschool children <5 years of age, there is still no
dedicated section for elderly patients within the GINA guideline
(10). It is also of relevance to understand whether the different
phenotypes asthma: early onset atopic and late-onset asthma,
would present with different responses to bronchodilator therapy
in old age.
Issues Working With Multiple Guidelines
As discussed in the previous section, different guidelines
provide different recommendations in terms of prescriptions
across patient age groups. The GINA, BTS, NICE, GEMA,
and CTS guidelines recommend SABA reliever and ICS
preventer as initial treatment for asthma. However, there
is less consensus on the subsequent add-on therapy for
asthma which remains uncontrolled after the initial therapy
in younger age-groups. In children (5–12 by BTS, 6–11
by GINA and CTS), LABA is recommended by the BTS
and CTS guidelines as an add-on if symptom control is
not achieved with ICS but is not recommended by GINA.
Additionally, in the preschool age-group, there are conflicting
recommendations regarding the use of LTRA as an alternative
to ICS (recommended by GINA, NICE, GEMA, and BTS, but
not CTS), and regarding stepping up ICS dosage to achieve
control (recommended by GINA, GEMA, and CTS, but not
BTS). The NICE guideline, on the other hand, recommended
stepping up to a moderate dose of ICS for 8 weeks following
initial SABA.
Working with multiple guidelines with different
recommendations for asthma management in childhood
patients may cause an additional challenge for primary care
physicians as highlighted previously by the Primary Care
Respiratory Society of UK (69).
Solutions
Despite the utility provided by subjective biomarker measures,
they may be unavailable in primary care practices due
to the barriers in implementation (70). Data sharing
across practices which allow easier physician access
to patients’ clinical records, including records of past
subjective measures, would provide a potential solution
to circumvent this challenge. This may also enable a
longer observation of patients’ medical history to aid in
differentiating between asthma, viral wheeze, and COPD in
primary care.
To improve cross-sharing of patients’ past medical records,
there is a need to improve electronic medical records (EMR)
systems which are often claims-based and lack uniformity
between systems. A potential solution will be the creation of a
uniform EMR template which brings together standardized past
medical records while enabling patient self-reported information
to be provided to primary care practitioners prior to consultation.
Creation of a uniform EMR template can be done by utilizing
research-based templates such as REDCap (71).
Moving forward, incorporation of clinical decision support
systems (CDSS) to EMR systems may aid physicians in
making informed clinical decisions despite conflicting
treatment guidelines across age-groups (72) and guide the
appropriate treatment while warning against the prescription
of non-indicated drugs based on the patients’ profile (73).
Ultimately, a global EMR for primary care, which is capable
of conducting machine-learning based on previous data
to provide future recommendations, may serve to guide
patient management in the lack of guidelines based on
strong evidence.
CONCLUSION
Phenotyping studies have shown that depending on the age of
onset, symptoms of asthma can represent distinct phenotypes
from asthma with later onset. Together with the changing
phenotypes across age are the changing challenges for diagnosis,
treatment, and control of asthma.
Guidelines for asthma management in young children and
the elderly are still based on weaker evidence, despite the
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higher hurdles in management. Differentiating asthma from
other diseases with similar presenting symptoms such as viral
wheeze and COPD remains a challenge. Regardless, there are
resources such as FeNO measurement and the mAPI (modified
Asthma Predictive Index), and spirometry which can assist
in the diagnosis of asthma for different age groups within
the primary care setting. Future developments in electronic
medical record systems to enable cross-sharing of clinical
history and implementation of clinical decision support systems
(CDSS) can potentially improve patient management across
different age-groups.
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